Epstein Secrets

ings that indicate a Covid-19 scam." Biggest Blowups Among Financial Funds Detailed. Reuters (3/29) reports that "financial institutions Nomura and Credit Suisse faced billions of dollars in losses after a highly leveraged U.S. investment fund called Archegos Capital defaulted on margin calls, triggering a f

been working beyond the drugmakers' initial experiments." The Minneapolis Star Tribune (3/29, Olson, 855K) says "clinical trials of the Moderna and Pfizer vaccines only looked at prevention of symptomatic infections, so the latest study of their effectiveness in health care and emergency medical worke

Trouble Vaccination Gender Gap Reveals Peril For Black Men Financial Times: India Airlifts Medical Supplies From Abroad As Covid 'Shakes Nation' Credit Suisse Shareholders Seek Removal Of Risk Chief After Twin Scandals How Draghi's Italy Became 'Model European' UK And European Banks Plan To Slash Business

s (4/25, Robbins, 20.6M) reports that according to the CDC, "more than five million people, or nearly 8 percent of those who got a first shot of the Pfizer or Moderna vaccines, have missed their second doses." The Times adds that as the US tries to encourage many people to receive a first dose, many he

lawmakers to respond to what turned out to be disastrous trades by Archegos." The trades "sent the stock of ViacomCBS into a tailspin. By the time Credit Suisse and Nomura, two prime brokers of Archegos, announced early Monday that they faced losses that could be 'highly significant' to the banks, rival fir

Pfizer Testing New Freeze-Dried Version Of Its COVID Vaccine. The Wall Street Journal (3/30, Hopkins, Subscription Publication, 8.41M) reports that Pfizer has announced plans to test a new version of its COVID vaccine, which will be freeze-fried in an effort to expand storage options for rural and low

4. None of New Leaf Ventures I, L.P., New Leaf Ventures IL, L.P., NLV-HI, the Management Company or any of their affiliates have any affilation with Credit Suisse nor any its affiliates (collectively, “Credit Suisse”). Credit Suisse has not compiled, reviewed or participated in the preparation of any of the per

Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region, and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories.